“El Periódico”, “La Vanguardia”, “Ara”, and other media, report on the new round of funding received by the biotech company Inbiomotion, a spin-off of IRB Barcelona specialized in predicting the risk of bone metastases in breast cancer patients. The company was founded in 2010 by Roger Gomis, ICREA researcher and group leader of Growth control and cancer metastasis at IRB Barcelona.
Led by "La Caixa", the round of funding closed with a concession of 2.2 million euros. Ysios Capital and Fundación Vila Casas also participated in this operation.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).